Latest news with #Cosmos
Daily Mirror
2 days ago
- General
- Daily Mirror
Gardeners urged to plant one common flower slugs absolutely hate
There are few plants that slugs enjoy nibbling more than the hosta, but instead of dousing yours in chemical insect repellants, try Diarmuid Gavin's more natural solution After hosting winter displays and spring bulbs, now's the time for summer colour in my pots. That's been my job this week and I like using terracotta pots because they complement most types of planting. They can dry out quickly so require a commitment to keeping them well watered throughout the warmer months. I've emptied the old compost around the garden beds and I am using a good-quality multi-purpose compost that will support my choice of plants. This, combined with fortnightly liquid feeding and deadheading, should ensure lots of flowers to enjoy over the next few months. As we are well past any fear of frost, there's plenty of plants that will thrive now. Tender bedding plants can be used and you may have been growing your own from seed which might be pot ready now. It is easy to be seduced by the trays of brightly coloured flowers for sale but in general it's a good idea to buy plants that have plenty of buds yet to blossom. I've chosen a mix of perennial and annuals, some old favourites and some new ones to try out. READ MORE: Homes with hanging baskets urged to repeat crucial 60 second task daily Bulbine 'Avera Sunset Orange' is a newbie. A perennial, it's also known as the burnt jelly plant as its succulent leaves have skin-healing properties, a bit like aloe vera. It has fleshy linear leaves and exotic-looking orange and yellow flowers. Hailing from South Africa, it can only manage outdoors here in the summer unless you are in the Scilly Isles or somewhere similar. It's a good plant for a balcony and then can be taken indoors over winter. Erigeron karvinskianus is an old reliable and one that I think looks great with its relaxed habit, the daisy flowers tumbling down the side of pots. Although it comes from Mexico, it's remarkably happy in our climate. It's great as an edging plant, tucked into cracks in paving or walls or simply as part of a mixed border and will grow in sun or partial shade in well-drained soil. Cerinthe purpurascens is a very easy-to-grow annual. Also known as honeywort, its pretty purple bell-shaped flowers are a magnet for bees and butterflies. These contrast beautifully with the silvery green oval leaves too. Cosmos is also a superb half hardy annual – I love the daisy-like flowers that usually come in white or pink but are also available in warmer yellows and oranges. I've a slightly complex relationship with hostas. Any plant that causes gardeners anxiety due to a creature nibbling on them, using chemical pesticides to kill them off, possibly isn't right for that gardener's plot. The slugs that feed on them make delicious food for our garden birds. And why do we want to poison any creature in our gardens? It's not really part of our nurturing nature is it? But there are some hostas that have a reputation for being slug resistant. I'm using a variety called 'Blue Umbrellas', which is one of the largest of the species and has giant blue-green heart shaped leaves. It should be the crowning glory of the new potted garden. Jobs to do in the garden this week Watch out for scarlet lily beetle and remove – they're crafty and will hop off the stem as you approach, so try and cup one hand below to catch them. Keep an eye out for slugs and snails who may tuck into your flowers and leafy vegetables. A shallow saucer of beer nightly beside your flowers is a good way of controlling them. Cut back lupins before they go to seed and you may get a second smaller flush. Cut back hardy geraniums that have finished flowering to ensure new growth. Keep roses well watered in warm weather and regularly check pots for watering. Peat-based compost can dry out, so it may need a complete dunking in a bucket of water until all the air bubbles are gone from soil. Warm weather can lead to an increase in algae and duckweed in your pond, so fish it out with a small fishing net or twirl it around a cane. Barley straw in the pond can help keep the problem at bay or if you can't get hold of any there are liquid products available that contain an extract of it which will do the same job. Keep your bird bath topped up for the birds. Divide irises after flowering – you only need do this process every few years but it will help to put new life into old stock. Why your roses aren't growing well in pots A reader wrote in to ask why his roses aren't doing well in pots. They're the right size and he followed the label instructions. I don't blame him for being baffled. Roses can grow very well in pots provided the conditions are right. In warm and windy weather pots can dry out fast so consistent watering is essential. However, they don't like being waterlogged as the roots can rot, so good drainage is important – pots must have drainage holes. Roses are hungry feeders and will benefit from a high potassium feed every two weeks in the growing season. Pot compost can become exhausted so top with fresh compost every year. With consistent moisture, good drainage, and feeding, your roses should bounce back. Plant of the week: Delphinium 'Faust' It's hard to compete with the glamour of delphiniums in full bloom, their stately stems covered in flowers. 'Faust' is a fine cultivar with an RHS Award of Garden Merit. It has rich blue double flowers with a dark eye and can grow to a height of 5-6ft. For best results, grow in well-drained soil and full sunshine. Give them adequate space as they don't like to be crowded and a sheltered spot is best. They make gorgeous cut flowers and provide vertical interest in the borders, flowering through the summer. Cut back faded spikes and you may get a second flush of flowers. For super blooms, thin shoots when young to leave just two or three spikes.
Mint
3 days ago
- Automotive
- Mint
After AI, Nvidia CEO Jensen Huang sees ‘multitrillion-dollar' opportunity in this tech sector. Details here
Nvidia CEO Jensen Huang has said other than artificial intelligence, robotics can turn out to be the chipmaker's biggest market for growth. The 62-year-old CEO also claimed that self-driving cars would be the first major commercial application for the technology. 'We have many growth opportunities across our company, with AI and robotics the two largest, representing a multitrillion-dollar growth opportunity,' Huang said on Wednesday at Nvidia's annual shareholders meeting, in response to a question from an attendee. A little over a year ago, Nvidia changed the way it reported its business units by grouping its automotive and robotics divisions into the same line item, CNBC reported. In May, Nvidia said automotive and robotics had $567 million in quarterly sales, which was about 1 per cent of the company's total revenue. That particular business unit was up 72 per cent on an annual basis. Nvidia's sales have been surging over the past three years due to heightened demand for the company's data centre graphics processing units, or GPUs, which are used to build and operate sophisticated AI applications such as OpenAI's ChatGPT. Total sales have soared from about $27 billion in its fiscal 2023 to $130.5 billion last year, and analysts are expecting nearly $200 billion in sales this year, according to the news agency. While robotics remains relatively small for Nvidia at the moment, Huang said applications will require the company's data centre AI chips to train the software as well as other chips installed in self-driving cars and robots, the news agency said. Huang highlighted Nvidia's Drive platform of chips, and software for self-driving cars, which Mercedes-Benz is using. He also said the company recently released AI models for humanoid robots called Cosmos. 'We're working towards a day where there will be billions of robots, hundreds of millions of autonomous vehicles, and hundreds of thousands of robotic factories that can be powered by Nvidia technology,' Huang said. Nvidia is increasingly offering more complementary technology alongside its AI chips, including software, a cloud service and networking chips to tie AI accelerators together. Huang said that Nvidia's brand is evolving with time, and that it's better described as an 'AI infrastructure' or 'computing platform' provider. 'We stopped thinking of ourselves as a chip company long ago,' Huang said.
Time of India
4 days ago
- Automotive
- Time of India
Nvidia CEO Jensen Huang: ‘We stopped thinking of ourselves as a chip company long ago', company now aims….
Nvidia CEO Jensen Huang has said that after artificial intelligence (AI), the chipmaker's next major business opportunity will be robotics. Speaking at the company's annual shareholder meeting, Huang said both AI and robotics represent what he believes a 'multitrillion-dollar growth opportunity'. 'We have many growth opportunities across our company, with AI and robotics the two largest, representing a multitrillion-dollar growth opportunity,' Huang said during the conference. Nvidia's robotics division has seen fast growth in the past. Currently making up just 1% of Nvidia's total revenue, the revenue brought in $567 million last quarter – a steep 72% rise from the previous year. 'We're working towards a day where there will be billions of robots, hundreds of millions of autonomous vehicles, and hundreds of thousands of robotic factories that can be powered by Nvidia technology,' Huang said. We stopped thinking ourself as a chip company: Nvidia CEO Huang also emphasized a shift in how the company sees itself. 'We stopped thinking of ourselves as a chip company long ago,' he said, adding that Nvidia is now focused on being an 'AI infrastructure' and 'computing platform' provider. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Buy Brass Idols - Handmade Brass Statues for Home & Gifting Luxeartisanship Buy Now Undo Self driving cars to be first commerce use of Nvidia's robotics technology: Jensen Huang During the annual shareholder meeting, Huang said that Nvidia's chips will be key not just for AI training, but also for software and hardware use in autonomous vehicles and robots. He named self-driving cars as the first major commercial use of Nvidia's robotics technology. Nvidia's Drive platform, a suite of chips and software for autonomous cars, is currently being used by Mercedes-Benz. The chipmaker recently introduced Cosmos, a line of AI models designed for humanoid robots. In a related news, Nvidia has surpassed Microsoft and Apple to become the world's most valuable company with a market cap of around $3.75 trillion. The company has rebounded strongly since a market dip earlier this year, which was caused by concerns about competition from China's DeepSeek AI. Redmi Pad 2: Know these Things Before Buying!
CNBC
4 days ago
- Automotive
- CNBC
Nvidia CEO says robotics is chipmaker's biggest opportunity after AI
Nvidia CEO Jensen Huang said that, other than artificial intelligence, robotics represents the chipmaker's biggest market for potential growth, and that self-driving cars would be the first major commercial application for the technology. "We have many growth opportunities across our company, with AI and robotics the two largest, representing a multitrillion-dollar growth opportunity," Huang said on Wednesday, at Nvidia's annual shareholders meeting, in response to a question from an attendee. A little over a year ago, Nvidia changed the way it reported its business units to group both its automotive and robotics divisions into the same line item. In May, Nvidia said that the business unit had $567 million in quarterly sales, or about 1% of the company's total revenue. Automotive and robotics was up 72% on an annual basis. Nvidia's sales have been surging over the past three years due to unyielding demand for the company's data center graphics processing units (GPUs), which are used to build and operate sophisticated AI applications like OpenAI's ChatGPT. Total sales have soared from about $27 billion in its fiscal 2023 to $130.5 billion last year, and analysts are expecting nearly $200 billion in sales this year, according to LSEG. The stock climbed to a record on Wednesday, lifting Nvidia's market cap to $3.75 trillion, putting it just ahead of Microsoft as the most valuable company in the world. While robotics remains relatively small for Nvidia at the moment, Huang said that applications will require the company's data center AI chips to train the software as well as other chips installed in self-driving cars and robots. Huang highlighted Nvidia's Thrive platform of chips, and software for self-driving cars, which Mercedes-Benz is using. He also said that the company recently released AI models for humanoid robots called Cosmos. "We're working towards a day where there will be billions of robots, hundreds of millions of autonomous vehicles, and hundreds of thousands of robotic factories that can be powered by Nvidia technology," Huang said. Nvidia has increasingly been offering more complementary technology alongside its AI chips, including software, a cloud service, and networking chips to tie AI accelerators together. Huang said Nvidia's brand is evolving, and that it's better described as an "AI infrastructure" or "computing platform" provider. "We stopped thinking of ourselves as a chip company long ago," Huang said. At the annual meeting, shareholders approved the company's executive compensation plan and reelected all 13 board members. Outside shareholder proposals to produce a more detailed diversity report and change shareholder meeting procedure did not pass.
Yahoo
6 days ago
- Business
- Yahoo
Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech
CHICAGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the 'Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its entry into the U.S. market and the launch of U.S.-based manufacturing through a strategic agreement with DolCas Biotech LLC ('DolCas'), a New Jersey-based developer and manufacturer of clinically studied nutraceutical ingredients. Cosmos Health is set to commence production in the United States at GMP-certified (Good Manufacturing Practice) facilities, marking a significant milestone in the Company's operational expansion. This move not only mitigates tariff exposure and cross-border logistical risks but also enhances production control beyond its existing European footprint, positioning Cosmos to scale efficiently in the global healthcare market. The agreement strengthens Cosmos Health's position in the premium nutraceuticals space and supports its broader strategy to expand its portfolio with scientifically backed, high-efficacy ingredients, while also leveraging DolCas's expertise in clinically validated formulations and vertically integrated manufacturing. K. Gnaneshwar Rao, CEO at DolCas Biotech, commented: 'We are thrilled to partner with Cosmos and are eager to build on this collaboration with a wide range of innovative products that will benefit both companies. Cosmos, under the visionary leadership of CEO Greg Siokas, has built an impressive portfolio of brands and products. His forward-thinking approach aligns perfectly with our values and ambitions. We see this as the beginning of a strong, strategic partnership and look forward to supporting Cosmos' continued growth in the United States and globally.' Greg Siokas, CEO of Cosmos Health, stated: 'We are proud to reach this important milestone as we commence production in the United States through our agreement with DolCas Biotech, a partner widely recognized for its commitment to quality and innovation. This strategic move strengthens our supply chain, enhances production oversight, and positions Cosmos for scalable global growth. It also reduces exposure to tariff-related risks, adding resilience amid shifting trade dynamics.' About DolCas Biotech LLCDolCas Biotech LLC is a U.S.-based developer and marketer of branded, science-backed nutraceutical ingredients, founded in 2007 as an extension of Orcas Naturals founded in 1993. Its portfolio includes, among others, clinically supported products such as Curcugen® (turmeric), Ginfort® (ginger), Morikol® (marine collagen), and TruOliv® (olive polyphenols). Through its dedicated manufacturing arm in India, the company maintains full vertical integration and strict control over ingredient quality. Its facilities are GMP-certified, FDA-registered, and UL-audited, underscoring a strong commitment to regulatory excellence and product integrity. About Cosmos Health Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at as well as LinkedIn and X. Forward-Looking StatementsWith the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website ( The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact:BDG Communicationscosm@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
